Mittendorff Robert II
CIK: 0001476171
Mittendorff Robert II's purchase track record
Mittendorff Robert II has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 7/24/2025 | CARL | $20.00M | -10.0% | -8.3% | +8.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CARL | ▲ Buy | Open Market | 1,333,333 | $20.0M | 7/24/2025 | View on chart |
| CARL | ▼ Sell | Other | 2,376,472 | — | 7/24/2025 | View on chart |
| CARL | ▼ Sell | Other | 931,452 | — | 7/24/2025 | View on chart |
| CARL | ▼ Sell | Other | 3,680,506 | — | 7/24/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
CARL CFO Appointment and FY2026 Revenue Guidance Confirmed
Carlsmed announced Richard Heppenstall as its new chief financial officer, succeeding Leo Greenstein. The company also reaffirmed its FY2026 sales guidance of $74 million to $78 million, matching analyst estimates. BTIG kept its price target at $23 following the announcements.
CARL CFO Appointment and FY2026 Revenue Guidance Confirmed. Carlsmed announced Richard Heppenstall as its new chief financial officer, succeeding Leo Greenstein. The company also reaffirmed its FY2026 sales guidance of $74 million to $78 million, matching analyst estimates. BTIG kept its price target at $23 following the announcements.